Background: Pneumococcal meningitis is a severe infectious disease, which is characterized by high mortality and frequent development of residual neurological damage. Effective cerebroprotection can improve the outcome of bacterial purulent meningitis. The aim of the study: To evaluate the cerebroprotective properties of Mexidol in bacterial purulent meningitis on a model of pneumococcal meningitis under experimental conditions. Materials and methods: Cerebroprotective properties of Mexidol were evaluated on a model of bacterial pneumococcal meningitis in Wistar rats. Meningitis was modeled by introducing into the subarachnoid space a suspension containing S. pneumoniae at a concentration of 5*109 CFU/ml. The cerebroprotective effect was assessed by mortality, degree of neurological deficit, approximate behavioral activity, results of testing for short-term and long-term memory. Results: In the groups receiving the drug «Mexidol» in doses of 15 mg/kg and 7.5 mg/kg, mortality was less than in the control group by 15%. Rats treated with «Mexidol» at a dose of 15 mg/kg had a higher clinical assessment of health on the first and fifth day of observation compared with animals from the control group (p<0.05). Animals receiving «Mexidol» at a dose of 15 mg/kg had a lower degree of neurological deficit on the 1st, 5th and 8th day after modeling of pathology compared to the control group (p<0.05). The specific strength of rats treated with «Mexidol» at a dose of 15 mg/kg was higher compared to the control group (p<0.05). When comparing the motor activity of animals in the control group with the group receiving «Mexidol» at a dose of 15 mg/kg on the 1st and 10th day after modeling pneumococcal meningitis in the actimetry test on the infrared activity monitor IR Actimeter, it was found that the activity of rats in this group was higher compared to the control group (p<0.05). Conclusion: During the experiment, it was revealed that the drug «Mexidol» at a dose of 15 mg/kg has a cerebroprotective effect on the model of bacterial pneumococcal meningitis.
Background: Pneumococcal meningitis is a severe infectious disease, which is characterized by high mortality and frequent development of residual neurological damage. Effective cerebroprotection can improve the outcome of bacterial purulent meningitis. The aim of the study: To evaluate the cerebroprotective properties of Mexidol in bacterial purulent meningitis on a model of pneumococcal meningitis under experimental conditions. Materials and methods: Cerebroprotective properties of Mexidol were evaluated on a model of bacterial pneumococcal meningitis in Wistar rats. Meningitis was modeled by introducing into the subarachnoid space a suspension containing S. pneumoniae at a concentration of 5*109 CFU/ml. The cerebroprotective effect was assessed by mortality, degree of neurological deficit, approximate behavioral activity, results of testing for short-term and long-term memory. Results: In the groups receiving the drug «Mexidol» in doses of 15 mg/kg and 7.5 mg/kg, mortality was less than in the control group by 15%. Rats treated with «Mexidol» at a dose of 15 mg/kg had a higher clinical assessment of health on the first and fifth day of observation compared with animals from the control group (p<0.05). Animals receiving «Mexidol» at a dose of 15 mg/kg had a lower degree of neurological deficit on the 1st, 5th and 8th day after modeling of pathology compared to the control group (p<0.05). The specific strength of rats treated with «Mexidol» at a dose of 15 mg/kg was higher compared to the control group (p<0.05). When comparing the motor activity of animals in the control group with the group receiving «Mexidol» at a dose of 15 mg/kg on the 1st and 10th day after modeling pneumococcal meningitis in the actimetry test on the infrared activity monitor IR Actimeter, it was found that the activity of rats in this group was higher compared to the control group (p<0.05). Conclusion: During the experiment, it was revealed that the drug «Mexidol» at a dose of 15 mg/kg has a cerebroprotective effect on the model of bacterial pneumococcal meningitis.